Search research articles
Contact Us
Filters
Showing results (231-240 of 377) with videos related to
Page
of 38
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 17, 2021
Immune-related Gene Expression Predicts Response to Neoadjuvant Chemotherapy but not Additional Benefit from PD-L1 Inhibition in Women with Early Triple-negative Breast Cancer
Bruno V Sinn, Sibylle Loibl, Claus A Hanusch, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 15, 2019
NAB-Paclitaxel Improves Disease-Free Survival in Early Breast Cancer: GBG 69-GeparSepto
Michael Untch, Christian Jackisch, Andreas Schneeweiss, et al.
The New England Journal of Medicine
|
September 16, 2024
Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer
Peter Schmid, Javier Cortes, Rebecca Dent, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 5, 2024
An Analysis of PIK3CA Hotspot Mutations and Response to Neoadjuvant Therapy in Patients with Breast Cancer from Four Prospective Clinical Trials
Paul Jank, Thomas Karn, Marion van Mackelenbergh, et al.
Journal of the National Cancer Institute
|
June 8, 2018
Adjuvant Anti-HER2 Therapy, Treatment-Related Amenorrhea, and Survival in Premenopausal HER2-Positive Early Breast Cancer Patients
Matteo Lambertini, Christine Campbell, José Bines, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 12, 2018
Intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for neoadjuvant treatment of high-risk early breast cancer (GeparOcto-GBG 84): A randomised phase III trial
Andreas Schneeweiss, Volker Möbus, Hans Tesch, et al.
Breast Cancer Research and Treatment
|
November 3, 2010
Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials
Gunter von Minckwitz, Michael Untch, Eveline Nüesch, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 11, 2023
Caveolin Gene Expression Predicts Clinical Outcomes for Early-Stage HER2-Negative Breast Cancer Treated with Paclitaxel-Based Chemotherapy in the GeparSepto Trial
Terence M Williams, Andreas Schneeweiss, Christian Jackisch, et al.
Geburtshilfe Und Frauenheilkunde
|
September 14, 2023
Treatment of Early Breast Cancer: The 18th St. Gallen International Breast Cancer Consensus Conference against the Background of Current German Treatment Recommendations
Michael Untch, Maggie Banys-Paluchowski, Sara Y Brucker, et al.
Geburtshilfe Und Frauenheilkunde
|
June 23, 2020
ABC5 International Consensus Conference on Advanced Breast Cancer, Lisbon, 16 November 2019: Commentary by the German panel of experts on the ABC5 voting results
Michael Untch, Rachel Würstlein, Diana Lüftner, et al.
Page
of 38
Search research articles
Search
Showing results (231-240 of 377) with videos related to
Sort By:
Page
of 38
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 17, 2021
Immune-related Gene Expression Predicts Response to Neoadjuvant Chemotherapy but not Additional Benefit from PD-L1 Inhibition in Women with Early Triple-negative Breast Cancer
Bruno V Sinn, Sibylle Loibl, Claus A Hanusch, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 15, 2019
NAB-Paclitaxel Improves Disease-Free Survival in Early Breast Cancer: GBG 69-GeparSepto
Michael Untch, Christian Jackisch, Andreas Schneeweiss, et al.
The New England Journal of Medicine
|
September 16, 2024
Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer
Peter Schmid, Javier Cortes, Rebecca Dent, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 5, 2024
An Analysis of PIK3CA Hotspot Mutations and Response to Neoadjuvant Therapy in Patients with Breast Cancer from Four Prospective Clinical Trials
Paul Jank, Thomas Karn, Marion van Mackelenbergh, et al.
Journal of the National Cancer Institute
|
June 8, 2018
Adjuvant Anti-HER2 Therapy, Treatment-Related Amenorrhea, and Survival in Premenopausal HER2-Positive Early Breast Cancer Patients
Matteo Lambertini, Christine Campbell, José Bines, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 12, 2018
Intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for neoadjuvant treatment of high-risk early breast cancer (GeparOcto-GBG 84): A randomised phase III trial
Andreas Schneeweiss, Volker Möbus, Hans Tesch, et al.
Breast Cancer Research and Treatment
|
November 3, 2010
Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials
Gunter von Minckwitz, Michael Untch, Eveline Nüesch, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 11, 2023
Caveolin Gene Expression Predicts Clinical Outcomes for Early-Stage HER2-Negative Breast Cancer Treated with Paclitaxel-Based Chemotherapy in the GeparSepto Trial
Terence M Williams, Andreas Schneeweiss, Christian Jackisch, et al.
Geburtshilfe Und Frauenheilkunde
|
September 14, 2023
Treatment of Early Breast Cancer: The 18th St. Gallen International Breast Cancer Consensus Conference against the Background of Current German Treatment Recommendations
Michael Untch, Maggie Banys-Paluchowski, Sara Y Brucker, et al.
Geburtshilfe Und Frauenheilkunde
|
June 23, 2020
ABC5 International Consensus Conference on Advanced Breast Cancer, Lisbon, 16 November 2019: Commentary by the German panel of experts on the ABC5 voting results
Michael Untch, Rachel Würstlein, Diana Lüftner, et al.
Page
of 38